Navigation Links
Reportlinker Adds Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Date:8/31/2010

ket, Japan, Diseased Population (in millions), 2001–2016 88

Figure 58: WH Disorder Therapeutics Market, Japan, Treatment Seeking Population (in millions), 2001–2016 89

Figure 59: WH Disorder Therapeutics Market, Japan, Diagnosed Population (in millions), 2001–2016 90

Figure 60: WH Disorder Therapeutics Market, Japan, Prescription Population (in millions), 2001–2016 91

Figure 61: WH Disorder Therapeutics Market, Global, R&D Pipeline by Indication (%), August 2010 92

Figure 62: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase (%), August 2010 93

Figure 63: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market (%), August 2010 94

Figure 64: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in the Endometriosis Therapeutics Market (%), August 2010 96

Figure 65: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market (%), August 2010 98

Figure 66: WH Disorder Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 106

Figure 67: WH Disorder Therapeutics Market, Global, Revenue of Top Five Players ($m), 2009 107

Figure 68: WH Disorder Therapeutics Market, Global, Average value, Revenue of Top Five Players ($m), 2009 107

Figure 69: WH Disorder Therapeutics Market, SWOT Analysis, Pfizer, 2009 109

Figure 70: WH Disorder Therapeutics Market, SWOT Analysis, Eli Lilly, 2009 110

Figure 71: WH Disorder Therapeutics Market, SWOT Analysis, Merck, 2009 111

Figure 72: WH Disorder Therapeutics Market, SWOT Analysis, Procter & Gamble, 2009 113

Figure 73: WH Disorder Therapeutics Market, SWOT Analysis, Hoffman-La Roche, 2009 116

Figure 74: WH Disorder Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2010 117

Figure 75: WH Disorder Therapeutics Market, Global, M&A Deals by Deal T
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
2. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
3. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
4. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
5. Reportlinker Adds Advances in Biopharmaceutical Technology in China
6. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
7. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
8. Reportlinker Adds Stem Cells Market And Applications. 2009-2015
9. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
10. Reportlinker Adds Global Nucleic Acid Testing Industry
11. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, today reported financial and operational results for the ... of 2009, PharmAthene recognized revenues of $5.5 million compared ... Revenues for the most recent quarter consisted primarily ...
... (OTC Bulletin Board: DORB) (DOR or the Company), a ... the first quarter of 2009. DOR,s revenues for the ... to $0.7 million for the first quarter of 2008. ... research and development amounts drawn down from DOR,s NIH ...
... Study and Orphan Drug DesignationROCKVILLE, Md., May 15 ... pharmaceutical company developing therapeutics for the treatment of cancer ... candidates at the American Society of Clinical Oncology (ASCO) ... 2, 2009 in Orlando, Florida. Presentations include both ...
Cached Biology Technology:PharmAthene Reports First Quarter 2009 Financial and Operational Results 2PharmAthene Reports First Quarter 2009 Financial and Operational Results 3PharmAthene Reports First Quarter 2009 Financial and Operational Results 4PharmAthene Reports First Quarter 2009 Financial and Operational Results 5PharmAthene Reports First Quarter 2009 Financial and Operational Results 6PharmAthene Reports First Quarter 2009 Financial and Operational Results 7DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 2EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 3EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 4EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 5
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... the speed that ice travels in more than 200 outlet ... the 21st century could be significantly less than the upper ... a paper funded by the National Science Foundation (NSF) and ... While the study indicates that a melting Greenland,s contributions to ...
... Boston, MA A new study by Harvard School of ... high-density lipoprotein (HDL) cholesterol, the so-called "good" cholesterol, may not ... be harmful. , This is the first study to ... resides on the surface of HDL cholesterol may increase the ...
... Scientists at Cold Spring Harbor Laboratory (CSHL) and Memorial ... that commonly occurring large chromosomal deletions that are ... functionally linked genes whose loss, they posit, confers a ... closely at one large deletion -- a so-called copy-number ...
Cached Biology News:Analysis of speed of Greenland glaciers gives new insight for rising sea level 2Analysis of speed of Greenland glaciers gives new insight for rising sea level 3Some HDL, or 'good' cholesterol, may not protect against heart disease 2Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 2Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 3
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Biology Products: